Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Guy R Simpson

Showing results (11-20 of 19) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 19 results.
Molecular Therapy : the Journal of the American Society of Gene Therapy|September 16, 2010
The effect of cell cycle synchronization on tumor sensitivity to reovirus oncolysisLucy Heinemann, Guy R Simpson, Nicola E Annels, et al.
Molecular Therapy Oncolytics|March 5, 2021
Oncolytic Reovirus-Mediated Recruitment of Early Innate Immune Responses Reverses Immunotherapy Resistance in Prostate TumorsNicola E Annels, Guy R Simpson, Mick Denyer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 24, 2009
Synergistic effects of oncolytic reovirus and cisplatin chemotherapy in murine malignant melanomaHardev S Pandha, Lucy Heinemann, Guy R Simpson, et al.
Frontiers in Oncology|January 30, 2020
A Specific Blood Signature Reveals Higher Levels of S100A12: A Potential Bladder Cancer Diagnostic Biomarker Along With Urinary Engrailed-2 Protein DetectionAyssar A Elamin, Saskia Klunkelfuß, Susanne Kämpfer, et al.
Oncotarget|November 23, 2017
Inhibition of HOX/PBX dimer formation leads to necroptosis in acute myeloid leukemia cellsRaed A Alharbi, Hardev S Pandha, Guy R Simpson, et al.
BMC Cancer|June 8, 2011
Synergistic effects of oncolytic reovirus and docetaxel chemotherapy in prostate cancerLucy Heinemann, Guy R Simpson, Angela Boxall, et al.
Molecular Therapy Oncolytics|July 11, 2018
Oncolytic Immunotherapy for Bladder Cancer Using Coxsackie A21 VirusNicola E Annels, Mehreen Arif, Guy R Simpson, et al.
BMC Cancer|April 14, 2022
HOX and PBX gene dysregulation as a therapeutic target in glioblastoma multiformeEinthavy Arunachalam, William Rogers, Guy R Simpson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 6, 2019
Phase I Trial of an ICAM-1-Targeted Immunotherapeutic-Coxsackievirus A21 (CVA21) as an Oncolytic Agent Against Non Muscle-Invasive Bladder CancerNicola E Annels, David Mansfield, Mehreen Arif, et al.
Pageof 2

Showing results (11-20 of 19) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 19 results.
Molecular Therapy : the Journal of the American Society of Gene Therapy|September 16, 2010
The effect of cell cycle synchronization on tumor sensitivity to reovirus oncolysisLucy Heinemann, Guy R Simpson, Nicola E Annels, et al.
Molecular Therapy Oncolytics|March 5, 2021
Oncolytic Reovirus-Mediated Recruitment of Early Innate Immune Responses Reverses Immunotherapy Resistance in Prostate TumorsNicola E Annels, Guy R Simpson, Mick Denyer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 24, 2009
Synergistic effects of oncolytic reovirus and cisplatin chemotherapy in murine malignant melanomaHardev S Pandha, Lucy Heinemann, Guy R Simpson, et al.
Frontiers in Oncology|January 30, 2020
A Specific Blood Signature Reveals Higher Levels of S100A12: A Potential Bladder Cancer Diagnostic Biomarker Along With Urinary Engrailed-2 Protein DetectionAyssar A Elamin, Saskia Klunkelfuß, Susanne Kämpfer, et al.
Oncotarget|November 23, 2017
Inhibition of HOX/PBX dimer formation leads to necroptosis in acute myeloid leukemia cellsRaed A Alharbi, Hardev S Pandha, Guy R Simpson, et al.
BMC Cancer|June 8, 2011
Synergistic effects of oncolytic reovirus and docetaxel chemotherapy in prostate cancerLucy Heinemann, Guy R Simpson, Angela Boxall, et al.
Molecular Therapy Oncolytics|July 11, 2018
Oncolytic Immunotherapy for Bladder Cancer Using Coxsackie A21 VirusNicola E Annels, Mehreen Arif, Guy R Simpson, et al.
BMC Cancer|April 14, 2022
HOX and PBX gene dysregulation as a therapeutic target in glioblastoma multiformeEinthavy Arunachalam, William Rogers, Guy R Simpson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 6, 2019
Phase I Trial of an ICAM-1-Targeted Immunotherapeutic-Coxsackievirus A21 (CVA21) as an Oncolytic Agent Against Non Muscle-Invasive Bladder CancerNicola E Annels, David Mansfield, Mehreen Arif, et al.
Pageof 2